New hope for lymphoma patients: drug duo may beat standard chemo

NCT ID NCT06284122

Disease control Sponsor: The Lymphoma Academic Research Organisation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a new combination of two drugs (mosunetuzumab and lenalidomide) against standard chemotherapy for people with untreated follicular lymphoma. About 790 participants will be randomly assigned to one of the two treatments. The goal is to see if the new combo keeps the cancer from growing longer than standard therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 790 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2024

Expected to finish

Apr 2034

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. 1\. Patient with histologically proven previously untreated CD20+ follicular lymphoma grade 1, 2, or 3a (including patient watched during up to 10 years after initial diagnosis) as assessed by the investigators according to the WHO 2016 classification12, or classical follicular lymphoma according to the WHO 2022 classification13. Diagnostic tissue must be available for central pathology review, exploratory endpoints and secondary data use. 2. FLIPI 2-5. 3. All Ann Arbor stages (including stage I if FLIPI ≥ 2). 4. Must need treatment as evidenced by at least one of the following criteria: 4.1. Bulky disease defined as one of the following: 4.1.1. a nodal or extranodal mass/lesion \> 70 mm in its largest diameter or, 4.1.2. involvement of at least 3 different nodal or extranodal sites (each with a diameter greater than \> 30 mm) 4.2. Presence of at least one of the following B symptoms within the prior 6 months: 4.2.1. fever (\> 38°C) of unclear etiology 4.2.2. night sweats 4.2.3. weight loss greater than 10% 4.3. Symptomatic splenomegaly 4.4. Symptomatic lesion: 4.4.1. painful lesion and/or 4.4.2. any compressive syndrome (for example, but not restricted to- ureteral, orbital, gastrointestinal) 4.5. Any one of the following cytopenias due to lymphoma: 4.5.1. hemoglobin \< 10g/dL (6.25 mmol/L) 4.5.2. platelets \<100 x 109/L, or 4.5.3. absolute neutrophil count (ANC) \< 1.5 x 109/L 4.6. Pleural or peritoneal serous effusion (irrespective of cell content) 4.7. Abnormal biological prognostic parameters: (item not applicable for Germany) 4.7.1. β2microglobulin \> ULN or 4.7.2. LDH \> ULN 5. At least one bi-dimensionally measurable nodal lesion, defined as \> 15 mm in its longest dimension, or at least one bi-dimensionally measurable extra nodal lesion, defined as \> 10 mm in its longest dimension (and FDG-avid lesion). 6. Participant who understood and voluntarily signed and dated an informed consent prior to any study-specific assessments/procedures. 7. Must be ≥ 18 years old at the time of signing the informed consent form (ICF). 8. ECOG performance status 0 to 2. 9. Estimated minimum life expectancy of 3 months. 10. Adequate hematological function within 28 days prior to randomization, including: 10.1. Absolute neutrophil count (ANC) ≥ 1 x 109/L 10.2. Platelet count ≥ 75 x 109/L, or ≥ 30 x 109/L if bone marrow infiltration or splenomegaly 10.3. Hemoglobin ≥ 8.0 g/dL (5 mmol/L) unless related to bone marrow infiltration or splenomegaly. Transfusion is allowed before starting treatment (no required window) 11. Normal laboratory values: 11.1. Measured or estimated creatinine clearance ≥ 40mL/min calculated by institutional standard method (MDRD or Cockcroft-Gault 11.2. AST or ALT ≤ 2.5 x the upper limit of normal (ULN), except in patients with documented liver or pancreatic involvement by lymphoma ≤ 5 x ULN 11.3. Serum total bilirubin ≤ 1.5 x ULN (or ≤ 3 x ULN for patients with Gilbert syndrome), except in patients with documented liver or pancreatic involvement by lymphoma ≤ 3 x ULN 12. LVEF within normal range (i.e. \> 50% as evaluated by Transthoracic Echocardiography or \> 45% as evaluated by isotopic method (MUGA scan). 13. Participants should be able to receive adequate prophylaxis and/or therapy for thromboembolic events (aspirin, low molecular weight heparin or direct oral anticoagulants). Patients with a curative anticoagulation therapy can be enrolled. A patient with deep vein thrombosis due to compressive syndrome is eligible if a curative anticoagulation therapy has been started at least 1 week before initiating study treatment: low molecular weight heparin possible at treatment onset, then direct oral anticoagulants according to local practices. 14. Must be able to adhere to the study visit schedule and other protocol requirements. 15. No more applicable following SM#14 16. Negative HIV test before randomization, with the following exception: Patients with a positive HIV test before randomization are eligible provided they are stable on antiretroviral therapy for at least 4 weeks, have a CD4 count ≥ 200/uL, have an undetectable viral load, and have not had a history of opportunistic infection attributable to AIDS within the last 12 months. 17. For women of childbearing potential (WOCBP) : * must have a negative result for pregnancy test (highly sensitive serum) within 7 days before randomization and within 7 days before initiation of study treatment. * must agree to abstain from becoming pregnant or breastfeeding, and agree to use highly effective contraceptive methods during study participation, and for at least 28 days after the final dose of lenalidomide (if applicable), 3 months after the final dose of mosunetuzumab and tocilizumab (if applicable), 12 months after the final dose of CHOP (if applicable), 6 months after the final dose of bendamustine (if applicable), 12 months after the final dose of rituximab (if applicable), and 18 months after the final dose of obinutuzumab (if applicable). 18. For men with a female partner of childbearing potential or pregnant female partner, men must remain abstinent or use a condom during the treatment period (including periods of treatment interruption), and for at least 07 days after the final dose of lenalidomide (if applicable), 2 months after the final dose of tocilizumab (if applicable), 6 months after the final dose of CHOP (if applicable), 3 months after the final dose of bendamustine (if applicable), 12 months after the final dose of rituximab (if applicable), and 3 months after the final dose of obinutuzumab (if applicable). Men must also agree to refrain from donating sperm from the first day of treatment until at least 7 days after the final dose of lenalidomide (if applicable), 2 months after the final dose of tocilizumab (if applicable), 6 months after the final dose of CHOP (if applicable), 3 months after the final dose of bendamustine (if applicable), 12 months after the final dose of rituximab (if applicable), and 3 months after the last dose of obinutuzumab (if applicable). 19. Participant covered by any social security system (France). 20. Participant who understands and speaks one of the country official languages, unless local regulation authorizes independent translators. Exclusion criteria: 1. Grade 3b follicular lymphoma according to the WHO 2016 classification12, or follicular large B-cell lymphoma according to the WHO 2022 classification13 2. Suspicion or clinical evidence of transformed lymphoma at enrollment by investigator assessment. Examples: patients with high or intermediate high SUV (\>20) in any nodal or extranodal site particularly in the bones (vertebrae etc) unless biopsy proven to be genuine FL grade 1,2, 3A ; and/or discordant (e.g. SUV doubled) with SUV of other sites including the biopsy site.; and/or LDH \> 2.5 x ULN in a context of rapidly progressive disease, etc. Please contact the Coordinating Investigator / Sponsor to discuss such cases or if there is any doubt before considering enrolment. 3. Prior localized radiotherapy for the FL. 4. Prior history of another lymphoma. 5. Uncontrolled symptomatic pleural or serous effusion requiring urgent treatment (within one week of finding). Participants may only be enrolled after Coordinating investigator / sponsor approval once confirmed participant is durably asymptomatic after adequate pleural/serous drainage or only if an efficient drainage device (e.g.pleurX™) is in place before randomization. 6. Uncontrolled symptomatic ureterohydronephrosis resulting in renal failure. Participants with adequate management i.e. ureteral catheter or double J stent allowing renal failure control are eligible only if urinary catheter is in place before randomization. 7. Presence or history of symptomatic or threatening lymphomatous epidural/nerve root lesion, even such participants whose disease is controlled by short course of steroids are NOT eligible. 8. Use of any standard or experimental anti-cancer drug therapy within 45 days of the start (Day 1) of study treatment. 9. Any contraindication to any drug contained in the study treatment control arms or in the Auxiliary Medicinal Products (AxMPs) 10. Systemic immunosuppressive medications (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) and corticosteroids on the long run with the following exceptions: inhaled steroids for asthma, topical steroids, or replacement or stress corticosteroids during the study at any time. Participants who require lymphoma symptom control during screening may receive corticosteroid \< or = 1mg/kg/day prednisone or equivalent for a maximum of 10 days prior to first dose of study treatment 11. Received a live, attenuated vaccine within 4 weeks before the first dose of study treatment, or in whom it is anticipated that such a live attenuated vaccine will be required during the study period or within 6 months after the final dose of study treatment. 12. Major surgery (excluding surgical documentation of FL) within 28 days prior to signing informed consent. 13. Seropositive for or active viral infection with hepatitis B virus (HBV): * HBsAg positive * HBsAg negative, anti-HBs positive and/or anti-HBc positive and detectable viral DNA (Patients who are HBsAg negative, anti-HBs positive and/or anti-HBc positive but viral DNA negative are eligible. They should be treated and perform testing at regular interval described in section Anti infectious prophylaxis; Patients who are seropositive due to a history of hepatitis B vaccine (anti-HBs positive) are eligible). 14. Known seropositive for, or active infection hepatitis C virus (HCV) (Patients who are positive for HCV antibody with a negative viral RNA are eligible). 15. Known or suspected hypersensitivity to biopharmaceuticals produced in CHO cells or any component of the mosunetuzumab, anti-CD20 mAb, tocilizumab, lenalidomide formulation, including mannitol; or to any of the excipients. 16. History of solid organ transplantation or allogeneic stem cell transplant (SCT). 17. Active autoimmune disease requiring treatment. 18. History of autoimmune disease, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, uveitis, or glomerulonephritis. * Participants with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible. * Participants with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study. * Participants with a remote history of, or well-controlled autoimmune disease, with a treatment-free interval from immunosuppressive therapy for 12 months may be eligible after review and discussion with the Coordinating investigator. 19. Participants with any active infection such as known active bacterial, viral (including SARS-CoV-2), fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds), known or suspected chronic active Epstein-Barr virus (EBV) infection are excluded. 20. Evidence of any significant, concomitant disease that could affect compliance with the protocol or interpretation of results, including, but not limited to: * significant cardiovascular disease \[e.g., Objective Class C or D heart diseases (cf. Classes of Heart Failure \| American Heart Association), myocardial infarction within the previous 6 months, unstable arrhythmia, or unstable angina) * significant pulmonary disease (such as obstructive pulmonary disease or history of bronchospasm) * clinically significant history of liver disease, including viral or other hepatitis, or cirrhosis * current or past history of central nervous system (CNS) disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease. Participants with a history of stroke who have not experienced a stroke or transient ischemic attack in the past 1 year and have no residual neurologic deficits as judged by the investigator are allowed. Participants with a history of epilepsy who have had no seizures in the past 2 years with or without anti-epileptic medications can be eligible. 21. History of confirmed progressive multifocal leukoencephalopathy (PML). 22. Known or suspected history of hemophagocytic lymphohistiocytosis (HLH). 23. History of erythema multiforme, Grade ≥3 rash, or blistering rash following prior treatment with immunomodulatory derivatives. 24. History of interstitial lung disease (ILD), drug-induced pneumonitis, and autoimmune pneumonitis. 25. Active malignancy other than the one treated in this research. Prior history of malignancies unless the patient has been free of the disease and therapy for ≥ 3 years. However, patients with a single occurrence of the following conditions that have been treated with curative intent are eligible: * Localized non-melanoma skin cancer. * Carcinoma in situ of the cervix. * Carcinoma in situ of the breast. * Incidental histologic finding of prostate cancer (T1a or T1b as per Tumor Node Metastasis \[TNM\] staging system) or prostate cancer. 26. Presence or history of CNS or meningeal involvement by lymphoma. 27. Pregnant, planning to become pregnant or lactating WOCBP. 28. Any significant medical conditions, including the presence of laboratory abnormality or psychiatric illness which places the patient at unacceptable risk if he/she were to participate in the study, and likely to interfere with participation in this clinical study (according to the investigator's decision) or which confounds the ability to interpret data from the study. 29. Person deprived of his/her liberty by a judicial or administrative decision. 30. Person hospitalized without consent. 31. Adult person under legal protection. 32. Patients with absolute lymphocyte count \> 20 G/L before randomization. Participants circulating lymphoma cell≥ 5 G/L must be discussed with the Sponsor before randomization. NB: for 29-31., if there is an individual benefit for such patients, an Ethics Committee will have to be informed case by case.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Follicular lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

110 sites in 7 countries. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

AGAPLESION DIAKONIEKLINIKUM ROTENBURG - Klinik für Hämatologie, Onkologie und Nephrologie
TERMINATED

Rotenburg (Wümme), 27356, Germany
AZ SINT-JAN BRUGGE - OOSTENDE AV - Service Hématologie
RECRUITING

Bruges, 8000, Belgium
BRUEDERKRANKENHAUS ST. JOSEF PADERBORN - Klinik für Hämatologie und Onkologie
RECRUITING

Paderborn, 33098, Germany
CENTRE HENRI BECQUEREL - Service Hématologie
RECRUITING

Rouen, 76038, France
CENTRE HOSPITALIER DE NIORT - Médecine interne
RECRUITING

Niort, 79021, France
CENTRE HOSPITALIER JEAN ROUGIER - Service d'Oncologie - Hématologie
RECRUITING

Cahors, 46005, France
CH ANNECY GENEVOIS - SITE D'ANNECY - Service Hématologie
RECRUITING

Pringy, 74374, France
CH DE BRETAGNE ATLANTIQUE - HOPITAL CHUBERT - Service Hématologie
RECRUITING

Vannes, 56017, France
CH DE LA COTE BASQUE - Service Hématologie
RECRUITING

Bayonne, 64100, France
CH DE VALENCIENNES - HOPITAL JEAN BERNARD - Service Hématologie
RECRUITING

Valenciennes, 59322, France
CH METROPOLE SAVOIE - SITE CHAMBERY - Service Hématologie
RECRUITING

Chambéry, 73011, France
CH d'AVIGNON - HOPITAL HENRI DUFFAUT - Service d'Onco-Hématologie
RECRUITING

Avignon, 84000, France
CHARITE UNIVERSITATSMEDIZIN BERLIN - Med. Klinik m. S. Hämatologie, Onkologie, Tumorimmunologie
RECRUITING

Berlin, 13353, Germany
CHD DE VENDEE - Service Hématologie
RECRUITING

La Roche-sur-Yon, 85925, France
CHI POISSY SAINT-GERMAIN-EN-LAYE - Service Hématologie
RECRUITING

Poissy, 78303, France
CHRU DE LILLE - HOPITAL CLAUDE HURIEZ - Service Hématologie
RECRUITING

Lille, 59037, France
CHU BRABOIS - Service Hématologie
RECRUITING

Vandœuvre-lès-Nancy, 54511, France
CHU BRETONNEAU - Service Cancérologie - Hématologie et Thérapie Cellulaire
RECRUITING

Tours, 37044, France
CHU DE BORDEAUX - HOPITAL HAUT-LEVEQUE - CENTRE FRANCOIS MAGENDIE - Service d'Hématologie et Thérapie Cellulaire
RECRUITING

Pessac, 33604, France
CHU DE GRENOBLE - Service Hématologie
RECRUITING

La Tronche, 38700, France
CHU DE LIEGE - Service Hématologie
RECRUITING

Liège, 4000, Belgium
CHU DE LIMOGES - HOPITAL DUPUYTREN - Service Hématologie Clinique et Thérapie Cellulaire
RECRUITING

Limoges, 87042, France
CHU DE MONTPELLIER - Département d'Hématologie Clinique
RECRUITING

Montpellier, 34090, France
CHU DE NANTES - Service Hématologie
RECRUITING

Nantes, 44093, France
CHU DE POITIERS - HOPITAL DE LA MILETRIE - Service d'Oncologie Hématologique et Thérapie Cellulaire
RECRUITING

Poitiers, 86021, France
CHU DE REIMS - HOPITAL ROBERT DEBRE - Service Hématologie
RECRUITING

Reims, 57092, France
CHU DIJON BOURGOGNE - Service Hématologie Clinique
RECRUITING

Dijon, 21000, France
CHU ESTAING - Service Thérapie Cellulaire et Hématologie Clinique
RECRUITING

Clermont-Ferrand, 63003, France
CHU JEAN MINJOZ - Service Hématologie
RECRUITING

Besançon, 25030, France
CHU LYON-SUD - Hématologie
RECRUITING

Pierre-Bénite, 69495, France
CHU PONTCHAILLOU - Hématologie Clinique
RECRUITING

Rennes, 35033, France
CHU UCL NAMUR - SITE GODINNE - Service Hématologie
RECRUITING

Yvoir, 5530, Belgium
GEMEINSCHAFTSKLINIKUM MITTELRHEIN GGMBH - Innere Medizin - Hämatologie/Onkologie
RECRUITING

Koblenz, 56073, Germany
GEORG-AUGUST-UNIV, GOETTINGEN - Klinik fur Haematologie und Medizinisched Onkologie
RECRUITING

Göttingen, 37075, Germany
GESUNDHEITSZENTRUM ST. MARIEN GMBH - Hämatologie/Onkologie
RECRUITING

Amberg, 92224, Germany
GH REGION MULHOUSE ET SUD ALSACE - HOPITAL EMILE MULLER - Service Hématologie
RECRUITING

Mulhouse, 68100, France
GOETHE UNIVERSITÄT FRANKFURT - Medizinische Klinik II Onkologie
RECRUITING

Frankfurt, Germany
GRAND HOPITAL DE CHARLEROI - Service Hématologie
RECRUITING

Charleroi, 6000, Belgium
GUSTAVE ROUSSY CANCER CAMPUS GRAND PARIS - Département Médecine Oncologique
RECRUITING

Villejuif, 94085, France
Gemeinschaftspraxis Fur Hamatologie Und Onkologie
RECRUITING

Münster, 48149, Germany
HELIOS UNIVERSITÄTSKLINIKUM WUPPERTAL - Hämatologie und Onkologie
RECRUITING

Wuppertal, 42283, Germany
HELORA - Hôpital de La Louvière - Site Jolimont - Service Hématologie Clinique
RECRUITING

La Louvière, 7100, Belgium
HFR Fribourg - Hématologie
RECRUITING

Villars-sur-Glâne, 1752, Switzerland
HOPITAL HENRI MONDOR - Unité Hémopathies Lymphoïdes
RECRUITING

Créteil, 94010, France
HOPITAL SAINT VINCENT-DE-PAUL - Service Hématologie
RECRUITING

Lille, 59020, France
HOPITAL SAINT-LOUIS - Service Hématologie
RECRUITING

Paris, 75475, France
HOSPITAL 12 DE OCTUBRE - Servicio de Hematología y Hemoterapia
RECRUITING

Madrid, 28041, Spain
HOSPITAL CENTRAL ASTURIAS - Servicio de Hematología
RECRUITING

Oviedo, 33011, Spain
HOSPITAL CLINIC BARCELONA - Hematology department
RECRUITING

Barcelona, 8036, Spain
HOSPITAL CLINICO DE VALENCIA - Servicio de Hematologia
RECRUITING

Valencia, 46010, Spain
HOSPITAL CLINICO SALAMANCA - Servicio de Hematologia
RECRUITING

Salamanca, 37007, Spain
HOSPITAL COSTA DEL SOL MARBELLA - Servicio de hematologia
RECRUITING

Marbella, 29603, Spain
HOSPITAL DE LA SANTA CREU I SANT PAU - Servicio de Hematología
RECRUITING

Barcelona, 8025, Spain
HOSPITAL DURAN I REYNALS - ICO Oncologia
RECRUITING

Barcelona, 08908, Spain
HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARANON - Servicio de Hematología-UTMO
RECRUITING

Madrid, 28007, Spain
HOSPITAL PUERTA DEL HIERRO - Servicio Hematologia
RECRUITING

Madrid, 28222, Spain
HOSPITAL UNIVERSITARIO ARNAU DE VILANOVA - Servicio Hematologia
RECRUITING

Lleida, 25198, Spain
HOSPITAL UNIVERSITARIO DE ALBACETE-Servicio de Hematologia
RECRUITING

Albacete, 02006, Spain
HOSPITAL UNIVERSITARIO DE LA PRINCESA - Hematología
RECRUITING

Madrid, 28006, Spain
HOSPITAL UNIVERSITARIO DR. NEGRIN-Servicio de Hematologia
RECRUITING

Las Palmas de Gran Canaria, 35010, Spain
HOSPITAL UNIVERSITARIO FUNDACION ALCORCON - Consulta de Hematología Hospital de Día Médico
RECRUITING

Madrid, 28922, Spain
HOSPITAL VALL D'HEBRON - Hematology Service
RECRUITING

Barcelona, 8035, Spain
Helios Klinikum Berlin-Buch - Klinik für Hämatologie und Stammzelltransplantation
RECRUITING

Berlin, 13125, Germany
Hôpitaux Universitaires de Genève (HUG) - Hématologie
RECRUITING

Geneva, 1205, Switzerland
INSTITUT BERGONIE - Service d'Oncologie Médicale
RECRUITING

Bordeaux, 33076, France
INSTITUT CURIE - SITE SAINT-CLOUD - Service Hématologie
RECRUITING

Saint-Cloud, 92210, France
INSTITUT DE CANCEROLOGIE STRASBOURG EUROPE - Unité de Recherche Clinique
RECRUITING

Strasbourg, 67033, France
INSTITUT JULES BORDET - Service Hématologie
RECRUITING

Brussels, 1070, Belgium
INSTITUT PAOLI CALMETTES - Service Hématologie
RECRUITING

Marseille, 13273, France
INSTITUTO PORTUGUES DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL - Departamento Hematologia
RECRUITING

Lisbon, 1099, Portugal
IUCT ONCOPOLE - Service Hématologie
RECRUITING

Toulouse, 31059, France
Institut de Cancérologie et d'Hématologie Universitaire de Saint-Étienne - Service Hématologie
RECRUITING

Saint-Priest-en-Jarez, 42270, France
KLINIKEN MARIA HILF GMBH KRANKENHAUS ST. FRANZISK - Hämatologie, Onkologie & Gastroenterologie
RECRUITING

Mönchengladbach, 41063, Germany
KLINIKUM AM STEINENBERG REUTLINGEN GMBH - Medizinische Klinik I
RECRUITING

Reutlingen, 72764, Germany
KLINIKUM BREMEN-MITTE - Gesundheit Nord gGmbH - Hämatologisch-Onkologische Tagesklinik
RECRUITING

Bremen, 28205, Germany
KLINIKUM CHEMNITZ GGMBH - Klinik f. Innere Medizin III
RECRUITING

Chemnitz, 9116, Germany
KLINIKUM GROSSHADERN DER LMU MUNCHEN - Hämatologie und Onkologie allgemein
RECRUITING

München, 81377, Germany
KLINIKUM RECHTS DER ISAR, III MED KLINIK DER TU - Hämatologie und Onkologie
RECRUITING

München, 81675, Germany
KLINIKUM REGION HANNOVER GMBH KLINIK FÜR HÄMATOLOGIE-Onkologie und immunologie
RECRUITING

Hanover, 30459, Germany
Kantonsspital Baselland - Zentrum Onkologie & Hämatologie
WITHDRAWN

Liestal, 4410, Switzerland
Kantonsspital Graubunden - Departement Innere Medizin Medizinische Onkologie und Hämatologie
RECRUITING

Chur, 7000, Switzerland
Kantonsspital Olten - Hämatologie
NOT_YET_RECRUITING

Olten, 4600, Switzerland
Kepler Universitaetsklinikum - Univ.-Klinik für Hämatologie und Internistische Onkologie
RECRUITING

Linz, 4021, Austria
Klinikum Wels-Grieskirchen GMBH - IVth Internal Department
RECRUITING

Wels, 4600, Austria
Krankenhaus der Barmherzigen Brüder Graz - Abteilung Für Innere Medizin I
RECRUITING

Graz, 8020, Austria
Krems University Hospital - Abteilung Für Innere Medizin 2
RECRUITING

Krems, 3500, Austria
LAKUMED KLINIKUM - Onkologisches und palliativmedizinisches Netzwerk Landshut
RECRUITING

Landshut, 84036, Germany
LKH HOCHSTEIERMARK - Department für Hämato-Onkologie
RECRUITING

Leoben, 8700, Austria
MEDICAL CENTER - UNIVERSITY OF FREIBURG - Klinik für Innere Medizin I Hämatologie, Onkologie und Stammzelltransplantation
RECRUITING

Freiburg im Breisgau, 79106, Germany
MVZ FÜR HÄMATOLOGIE UND ONKOLOGIE RAVENSBURG GMBH - Hematology
RECRUITING

Ravensburg, 86212, Germany
Medical University of Vienna - Department of Hematology and Hemostaseology
RECRUITING

Vienna, 1090, Austria
ONKOLOGIE LERCHENFELD - OncoResearch Lerchenfeld GmbH
WITHDRAWN

Hamburg, 22081, Germany
Oncology Institute of Southern Switzerland (IOSI) - Department of Oncology
RECRUITING

Bellinzona, 6500, Switzerland
Paracelsus Medical University - 3rd Medical Department
RECRUITING

Salzburg, 5020, Austria
SOZIALSTIFTUNG BAMBERG - KLINIKUM AM BRUDERWALD - Hämatologie und internistische Onkologie
RECRUITING

Bamberg, 96049, Germany
Spital STS AG - Onkologie und Hämatologiezentrum
RECRUITING

Thun, 3600, Switzerland
Stadtspital Zürich Triemli - Medizinische Onkologie und Hämatologie
WITHDRAWN

Zurich, 8063, Switzerland
UKSH UNIVERSITAETSKLINIKUM SCHLESWIG-HOLSTEIN - Med. Klinik II - Hämatologie und Onkologie
RECRUITING

Kiel, 24105, Germany
UNIV KLINIKUM ULM - INNERE MEDIZIN III - Service Hématologie
RECRUITING

Ulm, 89081, Germany
UNIVERSITAETSKLINIKUM ESSEN - Klinik f. Hämatologie
WITHDRAWN

Essen, 45147, Germany
UNIVERSITAIR ZIEKENHUIS GENT - Service Hématologie
RECRUITING

Ghent, 9000, Belgium
UNIVERSITATSKLINIKUM HALLE (SAALE) - Klinik für Innere Medizin IV
RECRUITING

Halle, 6097, Germany
UNIVERSITATSKLINIKUM LUBECK - Klinik für Hämatologie und Onkologie
RECRUITING

Lübeck, 23538, Germany
UNIVERSITATSKLINIKUM REGENSBURG - Klinik für Innere Medizin III
RECRUITING

Regensburg, 93053, Germany
UNIVERSITE CATHOLIQUE DE LOUVAIN SAINT-LUC - Service Hématologie
RECRUITING

Brussels, 1200, Belgium
UNIVERSITY WURZBURG - Hämatologie
RECRUITING

Würzburg, 97080, Germany
UNIVERSITÄT ROSTOCK - Hämatologie/Onkologie
RECRUITING

Rostock, 18057, Germany
UNIVERSITÄTSKLINIK DÜSSELDORF-Klinik für Hämatologie, Onkologie und Klinische Immunologie
RECRUITING

Düsseldorf, 40225, Germany
UNIVERSITÄTSKLINIKUM HEIDELBERG - Innere Medizin V
RECRUITING

Heidelberg, 69120, Germany
UNIVERSITÄTSKLINIKUM JENA-Klinik für Innere Medizin II
RECRUITING

Jena, 07747, Germany
Univ. Klinikum ST.PÖLTEN - Klinische Abteilung Für Innere Medizin 1
RECRUITING

Sankt Pölten, 3100, Austria
Universitätsklinikum Wiener Neustadt - Klinische Abteilung für Innere Medizin III
WITHDRAWN

Wiener Neustadt, 2700, Austria
Universitätsklinikum des Saarlandes - Klinik für Innere Medizin I - Onkologie, Hämatol. Immun. & Rheumatololgie
RECRUITING

Homburg, 66421, Germany
Universtatsklinikum Munster
RECRUITING

Münster, 48149, Germany
VIVANTES KLINIKUM AM URBAN - Hämatologie und Onkologie
RECRUITING

Berlin, 10967, Germany
WESTPFALZ KLINIKUM - Klinik für Innere Medizin I
RECRUITING

Kaiserslautern, 67655, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.